These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 34321842)

  • 1. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment.
    Axiaris G; Zampeli E; Michopoulos S; Bamias G
    World J Gastroenterol; 2021 Jul; 27(25):3762-3779. PubMed ID: 34321842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).
    Loras C; Gisbert JP; Saro MC; Piqueras M; Sánchez-Montes C; Barrio J; Ordás I; Montserrat A; Ferreiro R; Zabana Y; Chaparro M; Fernández-Bañares F; Esteve M;
    J Crohns Colitis; 2014 Nov; 8(11):1529-38. PubMed ID: 25052345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overuse of prophylaxis in HBsAg and/or anti-HBc positive patients after increasing awareness to prevent reactivation in patients receiving immunosuppressive therapies: How rational are our prophylaxis decisions according to the literature?
    Yenilmez E; Cetinkaya RA
    Infez Med; 2019 Sep; 27(3):299-307. PubMed ID: 31545774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.
    Tan J; Zhou J; Zhao P; Wei J
    Clin Rheumatol; 2012 Aug; 31(8):1169-75. PubMed ID: 22544263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.
    Elkady A; Aboulfotuh S; Ali EM; Sayed D; Abdel-Aziz NM; Ali AM; Murakami S; Iijima S; Tanaka Y
    World J Gastroenterol; 2013 Oct; 19(37):6214-20. PubMed ID: 24115819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment.
    Nakamoto S; Kanda T; Nakaseko C; Sakaida E; Ohwada C; Takeuchi M; Takeda Y; Mimura N; Iseki T; Wu S; Arai M; Imazeki F; Saito K; Shirasawa H; Yokosuka O
    Int J Mol Sci; 2014 Nov; 15(11):21455-67. PubMed ID: 25421241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab.
    Moses J; Alkhouri N; Shannon A; Raig K; Lopez R; Danziger-Isakov L; Feldstein AE; Zein NN; Wyllie R; Carter-Kent C
    Am J Gastroenterol; 2012 Jan; 107(1):133-8. PubMed ID: 21876562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.
    López-Serrano P; Pérez-Calle JL; Sánchez-Tembleque MD
    World J Gastroenterol; 2013 Mar; 19(9):1342-8. PubMed ID: 23538480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
    Fidan S; Capkın E; Arıca DA; Durak S; Okatan IE
    Int J Rheum Dis; 2021 Feb; 24(2):254-259. PubMed ID: 33244900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
    Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
    J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
    J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention.
    Sagnelli C; Pisaturo M; Calò F; Martini S; Sagnelli E; Coppola N
    World J Gastroenterol; 2019 Jul; 25(26):3299-3312. PubMed ID: 31341357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure.
    Wong GL; Wong VW; Yuen BW; Tse YK; Yip TC; Luk HW; Lui GC; Chan HL
    J Hepatol; 2020 Jan; 72(1):57-66. PubMed ID: 31499132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
    Feeney SA; McCaughey C; Watt AP; Agnaf MR; McDougall N; Wend UC; Gerlich WH; Coyle PV
    J Med Virol; 2013 Apr; 85(4):597-601. PubMed ID: 23359331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
    Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
    J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B; Samuel D
    Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients.
    Querido S; Weigert A; Adragão T; Rodrigues L; Jorge C; Bruges M; Machado D
    Transpl Infect Dis; 2019 Feb; 21(1):e13009. PubMed ID: 30295412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.